10. Oktober 2025 – Global private equity healthcare specialist ARCHIMED acquired a majority stake in ExcellGene and Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.

Walder Wyss advised the sellers on this transaction. The team was led by Luc Defferrard (Corporate/M&A, Partner) and included Caroline Sauthier (Corporate/M&A, Senior Associate), Matteo Berti (Corporate/M&A, Associate), Laura Luongo (Employment, Counsel), Fabienne Limacher (Partner, Tax), Daniela Hottiger (associate, Tax).